Abstract:OBJECTIVE:To evaluate the humoral and cell-mediated immune responses induced by a genetic vaccine expressing the Ag85B-ESAT6 fusion protein, and to investigate its protective effect against Mycobacterium tuberculosis (MTB) challenge.METHODS:Fifty BALB/c mice were randomized into 5 groups and subjected to the following treatments respectively: immunization with normal saline, BCG, pcDNA3, A(Z)-pcDNA3-E(F) and E(Z)-pcDNA3-A(F) for 3 times at 2-week intervals. The stimulation index (SI) of the splenic lymphocytes from the immunized mice was measured by the methyl thiazolyl tetrazolium (MTT) method, and the level of secreted IFN-gamma upon antigen-specific stimulation was detected by ELISA. The immunized mice were intravenously infected with 10(5) colony forming unit (CFU) of MTB H(37)Rv. The numbers of MTB CFU in spleens were determined 4 weeks later.RESULTS:The specific antibody titers in the sera of mice immunized with plasmid A(Z)-pcDNA3-E(F) and E(Z)-pcDNA3-A(F) were 1:1,000 and 1:1,500 respectively, and the SI was 2.2 and 2.4 respectively, while the SI of the normal saline group and the plasmid pcDNA3 immunized group was only 0.9 and 1.1 respectively. The IFN-gamma concentrations in cultured supernatant of splenic lymphocytes from mice immunized with plasmid A(Z)-pcDNA3-E(F) [(5.48 +/- 0.38) ng/ml] and E(Z)-pcDNA3-A(F) [(5.76 +/- 0.51) ng/ml] were significantly higher than those of the normal saline group [(0.50 +/- 0.25) ng/ml] and the plasmid pcDNA3 immunized group [(1.20 +/- 0.33) ng/ml, P < 0.05], but were not significantly different with that of the BCG immunized group [(5.55 +/- 0.31) ng/ml]. Compared with plasmid pcDNA3 immunized group, the bacterial load (lg, CFU/g) in spleen was 6.08 +/- 0.25 which dramatically reduced in mice immunized with recombinant plasmids, but the protective efficacy of mice immunized with plasmid A(Z)-pcDNA3-E(F) (4.63 +/- 0.11) or E(Z)-pcDNA3-A(F) (4.50 +/- 0.32) was lower than that of the BCG vaccination group (4.09 +/- 0.27).CONCLUSION:The cell-mediated immune response induced by genetic vaccine expressing the Ag85B-ESAT6 fusion protein was similar to that induced by BCG immunization.

Subcutaneous Administration of Modified Vaccinia Virus Ankara Expressing an Ag85b-Esat6 Fusion Protein, but Not an Adenovirus-Based Vaccine, Protects Mice Against Intravenous Challenge with Mycobacterium Tuberculosis

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Enhancement Of Antituberculosis Immunity In A Humanized Model System By A Novel Virus-Vectored Respiratory Mucosal Vaccine

Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.

A Recombinant Adenovirus Expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium Tuberculosis Elicits Strong Antigen-Specific Immune Responses in Mice.

Intranasal Immunization with a Recombinant Adenovirus Encoding Multi-Stage Antigens of Mycobacterium tuberculosis Preferentially Elicited CD8+ T Cell Immunity and Conferred a Superior Protection in the Lungs of Mice than Bacillus Calmette-Guerin

Heterologous Boosting with Recombinant Vsv-846 in Bcg-Primed Mice Confers Improved Protection Against Mycobacterium Infection

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Mycobacterium tuberculosis .

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.

The Development and Preliminary Evaluation of a Newmycobacterium Tuberculosisvaccine Comprising Ag85b, HspX and CFP-10:ESAT-6 Fusion Protein with CpG DNA and Aluminum Hydroxide Adjuvants

Subunit Vaccine Consisting Of Multi-Stage Antigens Has High Protective Efficacy Against Mycobacterium Tuberculosis Infection In Mice

Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX Against Mycobacterium Tuberculosis Infection in Mice

An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.

Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice

Immunity Characteristics Induced by a Genetic Vaccine Expressing Ag85B-ESAT6 Fusion Protein

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis

Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice Following a Single Intranasal Dose

Immune Responses and Protective Efficacy of the Gene Vaccine Expressing Ag85B and ESAT6 Fusion Protein Frommycobacterium Tuberculosis

Immunological Characteristics of Mycobacterium Tuberculosis Subunit Vaccines Immunized Through Different Routes.